Drug General Information
Drug ID	D07PQJ
Former ID	DIB002747
Drug Name	ARQ-087
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[524164]
Company	ArQule Inc
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Basic fibroblast growth factor receptor 1	Target Info	Inhibitor	[543495]
KEGG Pathway	MAPK signaling pathway
	Ras signaling pathway
	Rap1 signaling pathway
	PI3K-Akt signaling pathway
	Adherens junction
	Signaling pathways regulating pluripotency of stem cells
	Regulation of actin cytoskeleton
	Pathways in cancer
	Proteoglycans in cancer
	Prostate cancer
	Melanoma
	Central carbon metabolism in cancer
NetPath Pathway	TCR Signaling Pathway
PANTHER Pathway	Angiogenesis
	FGF signaling pathway
Pathway Interaction Database	Glypican 1 network
	Syndecan-4-mediated signaling events
	N-cadherin signaling events
	FGF signaling pathway
WikiPathways	Regulation of Actin Cytoskeleton
	Endochondral Ossification
	MAPK Signaling Pathway
	Mesodermal Commitment Pathway
	Hair Follicle Development: Induction (Part 1 of 3)
	Integrated Pancreatic Cancer Pathway
	Signaling Pathways in Glioblastoma
	Neural Crest Differentiation
	Signaling by FGFR
References
Ref 524164	ClinicalTrials.gov (NCT01752920) Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 543495	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.